Shingrix in Renal Transplant Recipients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 132 participants.

Also called NCT04128189

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 132 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04128189
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04128189. Randomized; no masking; primary purpose treatment. Start 2023-03-02 (actual); primary completion 2029-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Shingrix in Renal Transplant Recipients
Condition
Kidney Transplant Recipient Response to Shingrix Vaccine
Condition
Kidney Failure
Condition
Kidney Failure, Chronic
Condition
Kidney Transplantation
Condition
Herpes Zoster (HZ)
Intervention (Biological)
Shingrix
Lead sponsor
University of Colorado, Denver (class: other)
Collaborator
GlaxoSmithKline (class: industry)

Record details

Record id
cardio:ct-nct04128189
Content hash
d03865604ad7552890eeedf4980471dfd868499ca45acb9f76912d3094756b12